CorMedix Inc. SEC filings CRMD
CorMedix Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Sep 24, 2012. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 29, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 23, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| DEF 14A | Proxy statement | Oct 24, 2025 | Nov 10, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 15, 2025 | Sep 15, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 24, 2025 |
| DEF 14A | Proxy statement | Oct 8, 2024 | Nov 21, 2024 |
| DEFA14A | Additional proxy material | Sep 13, 2023 | — |
| DEF 14A | Proxy statement | Sep 13, 2023 | Oct 26, 2023 |
| DEFA14A | Additional proxy material | Aug 30, 2022 | — |
| DEF 14A | Proxy statement | Aug 30, 2022 | Oct 13, 2022 |
| DEFA14A | Additional proxy material | Oct 29, 2021 | — |
| DEF 14A | Proxy statement | Oct 29, 2021 | Dec 9, 2021 |
| DEF 14A | Proxy statement | Nov 4, 2020 | Dec 16, 2020 |
| DEF 14A | Proxy statement | Oct 17, 2019 | Nov 26, 2019 |
| DEFA14A | Additional proxy material | Oct 17, 2019 | — |
| DEFA14A | Additional proxy material | Nov 1, 2018 | — |
| DEF 14A | Proxy statement | Nov 1, 2018 | Dec 11, 2018 |
| DEFA14A | Additional proxy material | May 17, 2018 | — |
| DEF 14A | Proxy statement | May 17, 2018 | Jun 26, 2018 |
| PRE 14A | Preliminary proxy statement | May 7, 2018 | Jun 26, 2018 |
| DEFA14A | Additional proxy material | Aug 1, 2017 | — |
| DEF 14A | Proxy statement | Jun 29, 2017 | Jul 31, 2017 |
| PRE 14A | Preliminary proxy statement | Jun 16, 2017 | Jun 16, 2017 |
| DEFA14A | Additional proxy material | May 25, 2017 | — |
| DEFA14A | Additional proxy material | May 24, 2017 | — |
| DEFA14A | Additional proxy material | May 15, 2017 | — |
| DEFA14A | Additional proxy material | Apr 24, 2017 | — |
| DEF 14A | Proxy statement | Apr 24, 2017 | Jun 6, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2017 | Apr 7, 2017 |
| DEFA14A | Additional proxy material | May 4, 2016 | — |
| DEF 14A | Proxy statement | May 4, 2016 | Jun 7, 2016 |
| DEFA14A | Additional proxy material | Nov 25, 2015 | — |
| DEF 14A | Proxy statement | Nov 25, 2015 | Jan 19, 2016 |
| DEFA14A | Additional proxy material | Apr 22, 2015 | — |
| DEF 14A | Proxy statement | Apr 22, 2015 | Jun 4, 2015 |
| DEFA14A | Additional proxy material | May 16, 2014 | — |
| DEF 14A | Proxy statement | May 16, 2014 | Jun 25, 2014 |
| DEF 14A | Proxy statement | Jan 31, 2014 | Feb 28, 2014 |
| PRE 14A | Preliminary proxy statement | Jan 17, 2014 | Feb 28, 2014 |
| DEF 14A | Proxy statement | Jun 20, 2013 | Jul 30, 2013 |
| PRE 14A | Preliminary proxy statement | May 31, 2013 | May 31, 2013 |
| DEFA14A | Additional proxy material | May 31, 2013 | — |
| DEF 14A | Proxy statement | Oct 17, 2012 | Nov 30, 2012 |
| PRE 14A | Preliminary proxy statement | Sep 27, 2012 | Sep 27, 2012 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1410098
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.